TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer’s Disease
International Journal of Molecular Sciences · 11.05.2023 · 24 (10) · 8626
DOI: 10.3390/ijms24108626 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.05.2023. Verfasst von Francesca La Rosa und 9 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, MicroRNAs. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ricerca Corrente, Italian Ministry of Health, Fondazione Alessandro, Vincenzo Negroni Prati Morosini.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s Disease is the most common form of dementia; its key pathological findings include the deposition of extracellular-neurotoxic-plaques composed of amyloid-beta (Ab). AD-pathogenesis involves mechanisms that operate outside the brain, and new researches indicate that peripheral inflammation is an early event in the disease. Herein, we focus on a receptor known as triggering-receptor-expressed-on-myeloid-cells2 (TREM2), which promotes the optimal immune cells function required to attenuate AD-progression and is, therefore, a potential target as peripheral diagnostic and prognostic-biomarker for Alzheimer’s Disease. The objective of this exploratory study was to analyze: (1) soluble-TREM2 (sTREM2) plasma and cerebrospinal fluid concentration, (2) TREM2-mRNA, (3) the percentage of TREM2-expressing monocytes, and (4) the concentration of miR-146a-5p and miR-34a-5p suspected to influence TREM2 transcription. Experiments were performed on PBMC collected by 15AD patients and 12age-matched healthy controls that were unstimulated or treated in inflammatory (LPS) conditions and Ab42 for 24 h; Aβ42-phagocytosis was also analyzed by AMNIS FlowSight. Results although preliminary, due to limitations by the small sample-size, showed that in AD compared to HC: TREM2 expressing monocytes were reduced, plasma sTREM2 concentration and TREM2-mRNA were significantly upregulated and Ab42-phagocytosis was diminished (for all p < 0.05). miR-34a-5p expression was reduced (p = 0.02) as well in PBMC of AD, and miR-146 was only observed in AD cells (p = 0.0001).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.
- Department of Pathophysiology and Transplantation, University of Milan, 20100 Milan, Italy.
- Fondazione Ca' Granda, IRCCS Ospedale Maggiore Policlinico, 20122 Milan, Italy.
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20100 Milan, Italy.
ORCID-Profile: Francesca La Rosa, Simone Agostini, Daniela Galimberti, Marina Saresella, Mario Clerici
Förderung
- Ricerca Corrente, Italian Ministry of Health
- Fondazione Alessandro
- Vincenzo Negroni Prati Morosini
- Fondazione Romeo
- Enrica Invernizzi
Zitieren
APA
La Rosa, F., Agostini, S., Piancone, F., Marventano, I., Hernis, A., Fenoglio, C., Galimberti, D., Scarpini, E., Saresella, M., & Clerici, M. (2023). TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer’s Disease. International Journal of Molecular Sciences, 24(10), 8626. https://doi.org/10.3390/ijms24108626
Vancouver
La Rosa F, Agostini S, Piancone F, Marventano I, Hernis A, Fenoglio C, et al. TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer’s Disease. International Journal of Molecular Sciences. 2023;24(10):8626. doi:10.3390/ijms24108626
BibTeX
@article{LaRosa2023,
author = {La Rosa, Francesca and Agostini, Simone and Piancone, Federica and Marventano, Ivana and Hernis, Ambra and Fenoglio, Chiara and Galimberti, Daniela and Scarpini, Elio and Saresella, Marina and Clerici, Mario},
title = {TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {10},
pages = {8626},
doi = {10.3390/ijms24108626}
}
EUVIMED